GRV.F
Great Wall Motor Company Limited
FrankfurtEUREQUITY
Consumer Cyclical
DELAYED
Last price
0.91
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.91
Day high
0.91
Day low
0.91
Volume
80
Market cap
$7.78B
P/E (TTM)
6.07
52W range
0.91 – 2.12
Trailing performance
Returnvs SPY
1W
-1.31%
+0.1%
1M
-8.75%
-12.5%
3M
-24.08%
-27.2%
6M
-36.14%
-47.2%
YTD
-44.30%
-56.6%
1Y
-54.22%
-74.2%
3Y
-17.95%
-92.1%
5Y
-74.53%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GRV.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
141.56M
Total on file
Fundamentals
Market cap$7.78B
Enterprise value$-39.51B
Revenue (TTM)$227.91B
Gross profit$40.85B
EBITDA$14.74B
Net income$9.06B
EPS (TTM)$0.15
Free cash flow$35.18B
Total cash$63.44B
Total debt$16.10B
Book value / share$1.32
Shares outstanding2.31B
Float3.39B
Short % of float—
Dividend yield4.89%
Beta (5Y)0.70
Valuation & profitability ratios
Trailing P/E6.07
Forward P/E—
PEG ratio2.04
Price / sales—
Price / book0.69
EV / revenue-0.17
EV / EBITDA-2.68
Gross margin17.92%
Operating margin2.22%
Profit margin3.98%
Return on equity10.58%
Return on assets1.58%
Debt / equity18.19
Current ratio1.09
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $219.96B | $199.61B | $171.23B | $134.72B | — | +10.2% |
| Operating revenue | $219.96B | $199.61B | $171.23B | $134.72B | — | +10.2% |
| Cost of revenue | $182.62B | $162.75B | $141.77B | $110.74B | — | +12.2% |
| Gross profit | $37.33B | $36.86B | $29.45B | $23.98B | — | +1.3% |
| Research & development | $10.43B | $9.30B | $8.05B | $6.45B | — | +12.1% |
| Selling, general & admin | $8.80B | $7.10B | $7.35B | $6.20B | — | +24.0% |
| Total operating expense | $28.05B | $23.05B | $22.21B | $18.20B | — | +21.7% |
| Operating income | $9.28B | $13.82B | $7.24B | $5.78B | — | -32.8% |
| Net interest income | $329.45M | $242.33M | $252.90M | $461.29M | — | +35.9% |
| Pre-tax income | $11.76B | $14.23B | $7.82B | $8.81B | — | -17.3% |
| Tax provision | $1.89B | $1.57B | $801.24M | $553.74M | — | +20.9% |
| Net income | $9.87B | $12.66B | $7.02B | $8.27B | — | -22.1% |
| Net income to common | $9.87B | $12.66B | $7.02B | $8.27B | — | -22.1% |
| Basic EPS | — | 1.49 | 0.82 | 0.91 | 0.73 | — |
| Diluted EPS | — | 1.48 | 0.82 | 0.91 | 0.73 | — |
| EBIT | $12.49B | $15.12B | $8.77B | $9.52B | — | -17.4% |
| EBITDA | $13.96B | $16.00B | $9.30B | $9.90B | — | -12.8% |
| Basic shares | — | 8.50B | 8.56B | 9.08B | 9.21B | — |
| Diluted shares | — | 8.55B | 8.56B | 9.08B | 9.21B | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $28.85B | $30.77B | $35.27B | $26.90B | -6.2% |
| Cash & short-term investments | $63.95B | $47.17B | $39.38B | $41.09B | +35.6% |
| Accounts receivable | $9.60B | $7.27B | $7.19B | $6.61B | +32.0% |
| Inventory | $26.15B | $25.44B | $26.63B | $22.37B | +2.8% |
| Total current assets | $137.65B | $133.54B | $118.58B | $107.68B | +3.1% |
| Property, plant & equipment | $38.72B | $36.83B | $37.43B | $36.31B | +5.1% |
| Goodwill & intangibles | $24.54B | $24.79B | $23.42B | $20.25B | -1.0% |
| Total assets | $225.29B | $217.72B | $201.27B | $185.36B | +3.5% |
| Total current liabilities | $126.22B | $122.57B | $110.84B | $95.80B | +3.0% |
| Current debt | $42.01B | $45.65B | $40.16B | $40.49B | -8.0% |
| Long-term debt | $4.76B | $10.20B | $16.75B | $18.92B | -53.4% |
| Total debt | $50.14B | $57.96B | $57.93B | $60.78B | -13.5% |
| Total liabilities | $137.40B | $138.73B | $132.76B | $120.14B | -1.0% |
| Retained earnings | $66.25B | $61.39B | $52.73B | $49.18B | +7.9% |
| Shareholder equity | $87.89B | $78.98B | $68.50B | $65.20B | +11.3% |
| Working capital | $11.43B | $10.97B | $7.75B | $11.88B | +4.2% |
| Net tangible assets | $63.35B | $54.20B | $45.08B | $44.95B | +16.9% |
| Shares issued | 8.56B | 8.56B | 8.50B | 8.76B | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | — | — | $7.02B | $8.25B | $6.73B | — |
| Depreciation & amortisation | — | — | $7.72B | $6.52B | $5.51B | — |
| Stock-based compensation | — | — | $372.51M | $863.79M | $1.06B | — |
| Change in working capital | — | — | $2.29B | -$2.64B | $23.21B | — |
| Operating cash flow | — | — | $17.75B | $12.31B | $35.32B | — |
| Capital expenditure | -$11.51B | -$11.88B | -$16.71B | -$16.30B | — | +3.1% |
| Investing cash flow | -$29.15B | -$23.44B | -$10.45B | -$10.50B | — | -24.4% |
| Dividends paid | -$4.38B | -$3.35B | -$3.54B | -$1.23B | — | -30.8% |
| Financing cash flow | -$13.45B | -$12.01B | $1.05B | -$3.13B | — | -12.0% |
| Free cash flow | $28.85B | $15.89B | $1.04B | -$3.99B | — | +81.5% |
| End cash position | $25.28B | $27.23B | $35.27B | $26.90B | — | -7.2% |
| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Total revenue | $51.14B | $40.02B | $57.36B | +27.8% |
| Operating revenue | $51.14B | $40.02B | $57.36B | +27.8% |
| Cost of revenue | $42.48B | $32.88B | $50.03B | +29.2% |
| Gross profit | $8.66B | $7.14B | $7.33B | +21.3% |
| Research & development | $2.33B | $1.91B | $3.09B | +22.4% |
| Selling, general & admin | $715.72M | $3.23B | -$2.15B | -77.9% |
| Total operating expense | $4.29B | $6.35B | $2.42B | -32.4% |
| Operating income | $4.37B | $786.38M | $4.91B | +455.2% |
| Net interest income | -$1.11B | $1.03B | $484.31M | -207.5% |
| Pre-tax income | $5.15B | $1.85B | $2.24B | +178.3% |
| Tax provision | $566.91M | $100.20M | -$19.59M | +465.8% |
| Net income | $4.59B | $1.75B | $2.26B | +161.9% |
| Net income to common | $4.59B | $1.75B | $2.26B | +161.9% |
| Basic EPS | — | 0.21 | — | — |
| Diluted EPS | — | 0.21 | — | — |
| EBIT | $5.40B | $2.04B | $2.44B | +165.4% |
| EBITDA | $5.40B | $2.04B | $2.44B | +165.4% |
| Basic shares | — | 8.34B | — | — |
| Diluted shares | — | 8.34B | — | — |
| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $22.29B | $31.36B | $30.77B | -28.9% |
| Cash & short-term investments | $44.45B | $33.82B | $47.17B | +31.4% |
| Accounts receivable | $8.58B | $7.88B | $7.27B | +8.9% |
| Inventory | $33.26B | $32.61B | $25.44B | +2.0% |
| Total current assets | $135.79B | $126.52B | $133.54B | +7.3% |
| Property, plant & equipment | $38.80B | $37.43B | $36.83B | +3.7% |
| Goodwill & intangibles | $24.24B | $24.53B | $24.79B | -1.2% |
| Total assets | $222.13B | $212.55B | $217.72B | +4.5% |
| Total current liabilities | $123.96B | $114.40B | $122.57B | +8.4% |
| Current debt | $47.56B | $44.66B | $45.65B | +6.5% |
| Long-term debt | $6.98B | $9.28B | $10.20B | -24.8% |
| Total debt | $57.95B | $55.86B | $57.96B | +3.7% |
| Total liabilities | $137.68B | $129.89B | $138.73B | +6.0% |
| Retained earnings | $63.97B | $63.14B | $61.39B | +1.3% |
| Shareholder equity | $84.45B | $82.66B | $78.98B | +2.2% |
| Working capital | $11.84B | $12.13B | $10.97B | -2.4% |
| Net tangible assets | $60.21B | $58.13B | $54.20B | +3.6% |
| Shares issued | 8.56B | 8.56B | 8.56B | -0.0% |
| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Capital expenditure | -$2.64B | -$2.25B | -$5.04B | -17.4% |
| Investing cash flow | -$20.16B | $10.05B | -$18.80B | -300.6% |
| Dividends paid | -$226.79M | -$63.13M | -$339.10M | -259.3% |
| Financing cash flow | -$4.78B | $302.95M | -$4.43B | -1,679.3% |
| Free cash flow | $15.55B | -$11.23B | $8.55B | +238.5% |
| End cash position | $22.27B | $28.63B | $27.21B | -22.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $55.09B | +5.2% |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $244.84B | +9.9% |
| Next year | — | — | $280.95B | +14.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.65%
Held by institutions35.99%
Institutions holding234
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.93
-2.56% from price
SMA 20
0.96
-5.58% from price
SMA 50
1.00
-8.62% from price
SMA 100
1.14
-20.21% from price
SMA 200
1.33
-31.46% from price
EMA 12
0.94
-2.95% from price
EMA 26
0.96
-5.44% from price
EMA 50
1.01
-9.90% from price
RSI (14)
39.8
Neutral
MACD (12,26,9)
-0.02
Hist -0.00
ATR (14)
0.02
2.15% of price
Realised vol 30D
45.8%
Annualised
Bollinger upper
1.04
20, 2σ
Bollinger lower
0.89
20, 2σ
50 / 200 cross
Death
1.00 vs 1.33
Trend bias
Below 200
-31.46%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.11
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
45.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-57.0%
Peak to trough
Max drawdown 5Y
-78.6%
Peak to trough
ATR 14
0.02
2.15% of price
Beta (reported)
0.70
5Y monthly, from filing
Dividends & splits
Forward rate$0.04 / yr
Forward yield4.89%
5-year avg yield2.83%
Payout ratio38.81%
Ex-dividend dateJul 2, 2026
Next pay date—
Last split30:10
Split dateSep 30, 2015
Headlines
Billionaire Investor Stanley Druckenmiller Sold Broadcom, Intel, and Micron and Bought Another Chip Stock That Expects to Double Data Center Sales in 2027
Motley Fool · 10m ago
TME Pharma provides update on its activities
GlobeNewswire · 10m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 15m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 15m ago
Board Update
GlobeNewswire · 15m ago
Aegon implements EUR 150 million increase in share buyback program
GlobeNewswire · 15m ago
TOMY's "TOMICA XROSS RESCUE" Diorama-based Short Animation Series to Begin Streaming Aug. 26, 2026
PR Newswire · 15m ago
Holding(s) in Company
GlobeNewswire · 15m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.